Cargando…

PM359. A prospective cohort study for metabolic measures during antipsychotic treatments in patients with schizophrenia and schizoaffective disorder: A cross-sectional analysis of baseline data

Detalles Bibliográficos
Autores principales:	Kusumi, Ichiro, Arai, Yuki, Honda, Minoru, Ito, Koichi, Matsubara, Shigehiro, Matsuda, Yasuhiro, Matsuda, Yukihiko, Ohno, Kota, Okubo, Ryo, Sato, Norihiro, Takekita, Yoshiteru, Tochigi, Akihiko, Tsuchiya, Kiyoshi, Uemura, Keiichi, Yamada, Jun, Yamanaka, Hiroyoshi, Yoshimura, Bunta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616295/ http://dx.doi.org/10.1093/ijnp/pyw041.359

Ejemplares similares

Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder
por: Kusumi, Ichiro, et al.
Publicado: (2018)

PS36. Screening for diabetes using Japanese blood glucose monitoring guidance in patients with bipolar disorder treated with antipsychotics: A cross-sectional analysis of baseline data
por: Kusumi, Ichiro, et al.
Publicado: (2016)

Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database
por: Takekita, Yoshiteru, et al.
Publicado: (2020)

HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis
por: Takekita, Yoshiteru, et al.
Publicado: (2015)

Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia
por: Aoki, Yumi, et al.
Publicado: (2023)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa, Takaharu, et al.
Publicado: (2011)

359 Prevalence of Allergic Conjunctivitis in Childhood
por: Geraldini, Marcos, et al.
Publicado: (2012)

Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report
por: Tucker, Murray G., et al.
Publicado: (2016)

Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States
por: Joshi, Kruti, et al.
Publicado: (2016)

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
por: Huhn, Maximilian, et al.
Publicado: (2020)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
por: Fulone, Izabela, et al.
Publicado: (2021)

SAT-359 Hypercalcemia - Is This Sarcoidosis, Hyperparathyroidism, or Both?
por: Veeramachaneni, Ravali, et al.
Publicado: (2020)

Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first‐episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms
por: Takeuchi, Hiroyoshi, et al.
Publicado: (2021)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic, Martha, et al.
Publicado: (2018)

Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder
por: Chou, Fabienne, et al.
Publicado: (2016)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose, Mizue, et al.
Publicado: (2021)

P359: The consequences after an aesthetic procedure, is it worth it?
por: Triviño, M, et al.
Publicado: (2013)

SCHIZOAFFECTIVE DISORDER : CONSISTENCY OF DIAGNOSIS
por: Shrivastava, Amresh, et al.
Publicado: (1999)

Schizoaffective Disorder and Concurrent Rhabdomyolysis
por: Varkey, Thomas, et al.
Publicado: (2021)

To live with a Schizoaffective disorder
por: Arndtzén, Mats, et al.
Publicado: (2020)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

PUB1/359: The Use of the Internet for CME Purposes in Turkey
por: Yaman, H, et al.
Publicado: (1999)

Robust FCS Parsing: Exploring 211,359 Public Files
por: Bras, Anne E., et al.
Publicado: (2020)

RF07 | PSUN359 Alpelisib-induced Diabetic Ketoacidosis
por: Majumdar, Sachin, et al.
Publicado: (2022)

Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis.
por: Cegalis, J. A., et al.
Publicado: (1985)

Reducing the Diagnostic Heterogeneity of Schizoaffective Disorder
por: Seldin, Katherine, et al.
Publicado: (2017)

Cortical Alpha Activity in Schizoaffective Patients
por: Moeini, Mahdi, et al.
Publicado: (2017)

Schizoaffective disorder about 57 cases
por: Kammoun, I.
Publicado: (2021)

Valproate-induced hypothyroidism in schizoaffective disorder
por: Facucho-Oliveira, J., et al.
Publicado: (2022)

Novel cationic peptide TP359 down-regulates the expression of outer membrane biogenesis genes in Pseudomonas aeruginosa: a potential TP359 anti-microbial mechanism
por: Dosunmu, Ejovwoke F., et al.
Publicado: (2016)

K−p elastic scattering at 3.59 GeV/c
por: Lowman, A W, et al.
Publicado: (1973)

Newtronics Co. LTD Floppy Drive 0705449 D359T6
Publicado: (2017)

Parathyroid cysts: A review of 359 patients reported in the international literature
por: Papavramidis, Theodosios S., et al.
Publicado: (2018)

359 Epidemiology of Carbapenem-Resistant Enterobacteriaceae (CRE) at an Academic Medical Center
por: Leiner, Charles, et al.
Publicado: (2014)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

Behavioural Changes in a Patient With Schizoaffective Disorder
por: Varughese, Anto
Publicado: (2022)

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases
por: Kanahara, Nobuhisa, et al.
Publicado: (2023)

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication
por: Kinoshita, Toshihiko, et al.
Publicado: (2023)

PHD3 Regulates p53 Protein Stability by Hydroxylating Proline 359
por: Rodriguez, Javier, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s1djdjm7q3p70sjaonb8opncv1